Plasminogen activation without changes in tPA and PAI-1 in response to subcutaneous administration of ancrod

Thrombosis Research

Volumn 104, Issue 6, 2001, Pages 433-438

  Dempfle, Carl Erik ^a,c   Alesci, Sonja ^a   Kucher, Klaus ^b   Muller Peltzer H ^b   Rübsamen, Klaus ^b   Borggrefe, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Knoll AG   (Germany)

^c I Medizinische Klinik   (Germany)

Author keywords

Ancrod; Fibrin; Fibrin degradation products; Fibrinogen; Fibrinolysis; PAI 1; tPa

Indexed keywords

ANCROD; FIBRIN; PLACEBO; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; FIBRIN FORMATION; FIBRINOLYSIS; HUMAN; MALE; NORMAL HUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLUBILITY;

ADULT; ANCROD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRIN; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, SUBCUTANEOUS; KINETICS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0035894639     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(01)00391-7     Document Type: Article

References (22)

1. Therapeutic defibrination by ancrod (Arvin)
2. The proteolytic actions of ancrod on human fibrinogen and polypeptide chains
3. The action of Arvin on fibrin stabilizing factor (factor XIII)
4. Characterization of fibrin degradation products in patients on ancrod therapy: Comparison with fibrinogen derivatives produced by plasmin
5. SDS polyacrylamide gel characterization of serum FDP produced in response to Ancrod and Streptokinase/Plasminogen infusions in man
6. Analysis of fibrin formation and proteolysis during intravenous administration of ancrod
7. Improvement of the flow properties of human blood through subcutaneous administration of Arwin
8. Defibrinogenating enzymes
9. Intravenous ancrod for treatment of acute ischemic stroke
10. A functional photometric assay for plasma fibrinogen
11. A new immunoassay for soluble fibrin enables a more sensitive detection of the activation state of blood coagulation in vivo
12. Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin alpha-chain to fibrin polymerization site 'A': Effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN
13. Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay
14. The stimulatory effect of soluble fibrin on plasminogen activation by tissue plasminogen activator as studied by the Coa-set Fibrin Monomer Test
15. A quantitative enzyme immunoassay for primary fibrinogenolysis products in plasma
16. A monoclonal antibody-based enzyme immunoassay for fibrin degradation products in plasma
17. Ancrod causes rapid thrombolysis in patients with acute stroke
18. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke
19. Thrombolysis for acute ischaemic stroke
20. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices
21. Disruption of the plasminogen gene is mice abolishes wound healing after myocardial infarction
22. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke